Insider · CIK 0001181561
John C Reed
Files at JNJ (JOHNSON & JOHNSON), MDGL (MADRIGAL PHARMACEUTICALS, INC.). First filing Jul 18, 2025, latest Feb 18, 2026.
In brief
John C Reed files SEC Form 4 as officer and director at JNJ (JOHNSON & JOHNSON), and also at MDGL (MADRIGAL PHARMACEUTICALS, INC.). Since Jul 18, 2025, John C Reed has reported 0 open-market buys worth $0 and 3 open-market sells worth $20M, the latest filed on Feb 18, 2026.
A track record needs three past buys with six months of prices behind them; John C Reed has 0, so none is measured yet.
The newest scored trade: sold $13M of JNJ on Feb 17, 2026, filed Feb 18, 2026, scored 60 (notable). In the last 12 months: 0 buys worth $0 and 2 sells worth $17M.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
JNJ: JOHNSON & JOHNSON
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 60Notable | JOHNSON & JOHNSON | $13M 53,931 shares | -156% | +70% from low-1% from high | |
| 45Moderate | JNJsell JOHNSON & JOHNSON | $4.2M 21,721 shares | -67% | +39% from low0% from high | |
| 60Notable | JNJsell JOHNSON & JOHNSON | $3.1M 19,137 shares | -64% | +17% from low-2% from high |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Feb 17, 2026 | JNJ JOHNSON & JOHNSON | 53,931 0.00% of outstanding | $13M | Feb 17, 2026 | none |
| Oct 17, 2025 | JNJ JOHNSON & JOHNSON | 21,721 0.00% of outstanding | $4.2M | Oct 17, 2025 | $3.1M |
| Jul 17, 2025 | JNJ JOHNSON & JOHNSON | 19,137 0.00% of outstanding | $3.1M | Jul 17, 2025 | none |
Transactions
Every row this insider has filed, 40 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Aug 15, 2026 | MDGL MADRIGAL PHARMACEUTICALS, INC. | AGrant or award Common Stock | +647 | $0.00 | $0 | 647 | Aug 18, 2026 |
| Aug 15, 2026 | MDGL MADRIGAL PHARMACEUTICALS, INC. | AGrant or award Stock Option (Right to Buy)derivative | +1,078 | $0.00 | $0 | 1,078 | Aug 18, 2026 |
| May 1, 2026 | JNJ JOHNSON & JOHNSON | MOption exercise Common Stock | +25,255 | $0.00 | $0 | 35,913 | May 4, 2026 |
| May 1, 2026 | JNJ JOHNSON & JOHNSON | FTax withholding Common Stock | -11,002 | $229.85 | $2.5M | 24,911 | May 4, 2026 |
| May 1, 2026 | JNJ JOHNSON & JOHNSON | MOption exercise Restricted Share Unitsderivative | -25,255 | $0.00 | $0 | 0 | May 4, 2026 |
| Feb 15, 2026 | JNJ JOHNSON & JOHNSON | MOption exercise Common Stock | +1,349 | $0.00 | $0 | 12,007 | Feb 18, 2026 |
| Feb 15, 2026 | JNJ JOHNSON & JOHNSON | FTax withholding Common Stock | -385 | $243.45 | $94k | 11,622 | Feb 18, 2026 |
| Feb 15, 2026 | JNJ JOHNSON & JOHNSON | MOption exercise Common Stock | +1,847 | $0.00 | $0 | 13,469 | Feb 18, 2026 |
| Feb 15, 2026 | JNJ JOHNSON & JOHNSON | FTax withholding Common Stock | -528 | $243.45 | $129k | 12,941 | Feb 18, 2026 |
| Feb 17, 2026 | JNJ JOHNSON & JOHNSON | MOption exercise Common Stock | +21,721 | $157.92 | $3.4M | 34,662 | Feb 18, 2026 |
| Feb 17, 2026 | JNJ JOHNSON & JOHNSON | SOpen-market sale Common Stock | -21,721 | $243.00 | $5.3M | 12,941 | Feb 18, 2026 |
| Feb 17, 2026 | JNJ JOHNSON & JOHNSON | MOption exercise Common Stock | +29,927 | $156.15 | $4.7M | 42,868 | Feb 18, 2026 |
| Feb 17, 2026 | JNJ JOHNSON & JOHNSON | SOpen-market sale Common Stock | -29,927 | $243.00 | $7.3M | 12,941 | Feb 18, 2026 |
| Feb 17, 2026 | JNJ JOHNSON & JOHNSON | SOpen-market sale Common Stock | -2,283 | $243.00 | $555k | 10,658 | Feb 18, 2026 |
| Feb 15, 2026 | JNJ JOHNSON & JOHNSON | MOption exercise Restricted Share Unitsderivative | -1,349 | $0.00 | $0 | 1,349 | Feb 18, 2026 |
| Feb 15, 2026 | JNJ JOHNSON & JOHNSON | MOption exercise Restricted Share Unitsderivative | -1,847 | $0.00 | $0 | 3,692 | Feb 18, 2026 |
| Feb 15, 2026 | JNJ JOHNSON & JOHNSON | AGrant or award Employee Stock Options (Right to Buy)derivative | +49,382 | $0.00 | $0 | 49,382 | Feb 18, 2026 |
| Feb 15, 2026 | JNJ JOHNSON & JOHNSON | AGrant or award Restricted Share Unitsderivative | +3,546 | $0.00 | $0 | 3,546 | Feb 18, 2026 |
| Feb 17, 2026 | JNJ JOHNSON & JOHNSON | MOption exercise Employee Stock Options (Right to Buy)derivative | -21,721 | $0.00 | $0 | 21,721 | Feb 18, 2026 |
| Feb 17, 2026 | JNJ JOHNSON & JOHNSON | MOption exercise Employee Stock Options (Right to Buy)derivative | -29,927 | $0.00 | $0 | 59,854 | Feb 18, 2026 |
| Oct 17, 2025 | JNJ JOHNSON & JOHNSON | MOption exercise Common Stock | +21,721 | $157.92 | $3.4M | 32,379 | Oct 20, 2025 |
| Oct 17, 2025 | JNJ JOHNSON & JOHNSON | SOpen-market sale Common Stock | -21,721 | $192.71 | $4.2M | 10,658 | Oct 20, 2025 |
| Oct 17, 2025 | JNJ JOHNSON & JOHNSON | MOption exercise Employee Stock Options (Right to Buy)derivative | -21,721 | $157.92 | $3.4M | 43,442 | Oct 20, 2025 |
| Jul 17, 2025 | JNJ JOHNSON & JOHNSON | SOpen-market sale Common Stock | -19,137 | $163.55 | $3.1M | 10,658 | Jul 18, 2025 |
| May 1, 2025 | JNJ JOHNSON & JOHNSON | MOption exercise Common Stock | +25,255 | $0.00 | $0 | 40,797 | May 5, 2025 |
| May 1, 2025 | JNJ JOHNSON & JOHNSON | FTax withholding Common Stock | -11,002 | $156.31 | $1.7M | 29,795 | May 5, 2025 |
| May 1, 2025 | JNJ JOHNSON & JOHNSON | MOption exercise Restricted Share Unitsderivative | -25,255 | $0.00 | $0 | 25,255 | May 5, 2025 |
| Feb 15, 2025 | JNJ JOHNSON & JOHNSON | AGrant or award Employee Stock Options (Right to Buy)derivative | +89,781 | $0.00 | $0 | 89,781 | Feb 19, 2025 |
| Feb 15, 2025 | JNJ JOHNSON & JOHNSON | AGrant or award Restricted Share Unitsderivative | +5,539 | $0.00 | $0 | 5,539 | Feb 19, 2025 |
| Feb 15, 2025 | JNJ JOHNSON & JOHNSON | MOption exercise Common Stock | +1,350 | $0.00 | $0 | 15,927 | Feb 18, 2025 |
| Feb 18, 2025 | JNJ JOHNSON & JOHNSON | FTax withholding Common Stock | -385 | $156.15 | $60k | 15,542 | Feb 18, 2025 |
| Feb 15, 2025 | JNJ JOHNSON & JOHNSON | MOption exercise Restricted Share Unitsderivative | -1,350 | $0.00 | $0 | 2,698 | Feb 18, 2025 |
| May 1, 2024 | JNJ JOHNSON & JOHNSON | MOption exercise Common Stock | +25,255 | $0.00 | $0 | 25,561 | Oct 31, 2024 |
| May 1, 2024 | JNJ JOHNSON & JOHNSON | FTax withholding Common Stock | -10,984 | $144.59 | $1.6M | 14,577 | Oct 31, 2024 |
| May 1, 2024 | JNJ JOHNSON & JOHNSON | MOption exercise Restricted Share Unitsderivative | -25,255 | $0.00 | $0 | 50,510 | Oct 31, 2024 |
| May 1, 2024 | JNJ JOHNSON & JOHNSON | MOption exercise Common Stock | +22,255 | $0.00 | $0 | 22,561 | May 3, 2024 |
| May 1, 2024 | JNJ JOHNSON & JOHNSON | FTax withholding Common Stock | -10,984 | $144.59 | $1.6M | 11,577 | May 3, 2024 |
| May 1, 2024 | JNJ JOHNSON & JOHNSON | MOption exercise Restricted Share Unitsderivative | -22,255 | $0.00 | $0 | 53,510 | May 3, 2024 |
| Feb 15, 2024 | JNJ JOHNSON & JOHNSON | AGrant or award Employee Stock Options (Right to Buy)derivative | +65,163 | $0.00 | $0 | 65,163 | Feb 20, 2024 |
| Feb 15, 2024 | JNJ JOHNSON & JOHNSON | AGrant or award Restricted Share Unitsderivative | +4,048 | $0.00 | $0 | 4,048 | Feb 20, 2024 |
Questions about John C Reed
Answered from the filings on this page, as of the latest one.
Is John C Reed buying or selling?
In the last 12 months John C Reed reported 0 open-market buys worth $0 and 2 open-market sells worth $17M on SEC Form 4; the latest was sold $13M of JNJ on Feb 17, 2026. Grants, option exercises and tax withholding are not counted.
How did John C Reed's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and John C Reed has 0.
Where does John C Reed file Form 4?
John C Reed has filed Form 4 at JNJ (JOHNSON & JOHNSON) as EVP, Innovative Medicine, R&D; MDGL (MADRIGAL PHARMACEUTICALS, INC.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.